Want to join the conversation?
$LVLT, which competes with $CTL and $T, said it expects full year 2016 adjusted EBITDA growth of 10-12% compared to previous outlook of 9-12%. The company expects to generate free cash flow of $1.0-1.1Bil. Non-cash compensation estimate for 2016 is updated to $170MM from $130MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.